A Phase II Randomized Study of Enzalutamide+Leuprolide Versus Enzalutamide+Leuprolide+Abiraterone Acetate+Prednisone as Neoadjuvant Therapy for HIgh-Risk Prostate Cancer Undergoing Prostatectomy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone acetate; Leuprorelin; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 24 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 May 2019.
- 25 Sep 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 31 Aug 2018 Biomarkers information updated